Currently, treatment regimens for IDH-wt LGG in the NCCN treatment guidelines tend to be consistent with GBM, and the 3rd version of cIMPACT-NOW indicates that when IDH-wt diffuse astrocytoma has certain molecular pathological characteristics, it can be considered a WHO grade IV glioma; however, through our analysis of clinical information, molecular pathology, and gene expression, we found that there are still many differences between IDH-wt LGG and GBM (12, 13). This evidence concerns the gene IDH1 and central nervous system cancer.